AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction.
Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity.
The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body’s first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.
ADX-097, the lead product candidate from Q32’s complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
Country | n/a |
IPO Date | Mar 28, 2018 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 42 |
CEO | Jodie Pope Morrison |
Contact Details
Address: No Address available No city data available, | |
Website | n/a |
Stock Details
Ticker Symbol | n/a |
Exchange | NASDAQ |
Fiscal Year | n/a |
Reporting Currency | USD |
CIK Code | n/a |
CUSIP Number | n/a |
ISIN Number | US7469641051 |
Employer ID | - |
SIC Code | n/a |
Key Executives
Name | Position |
---|---|
Jodie Pope Morrison | Chief Executive Officer & Director |
Dr. Saul Fink Ph.D. | Chief Technology Officer |
Lee H. Kalowski M.B.A. | Chief Financial Officer & President |
David Appugliese J.D. | Senior Vice President & Head of People |
Dr. Jason A. Campagna M.D., Ph.D. | Chief Medical Officer |
Dr. Shelia M. Violette Ph.D. | Co-founder, Chief Scientific Officer & President of Research |
Kathryn E. Golden M.B.A. | Head of Chemistry, Manufacturing & Controls |
Maria Marzilli M.P.H. | Executive Vice President of Corporate Strategy & Program Operations |